Hospital

A recent study suggests that homologous and heterologous vaccines protect against the Omicron variant of COVID-19, but the heterologous appears more durable.

The interim analysis of the TROPION-Lung02 trial demonstrate an overall response rate of 37% in individuals who were treated with datopotamab deruxtecan and pembrolizumab.

There are several key areas of risk that infusion practices are likely to face at some point, and proactively preparing for these events can help ensure a positive outcome.

Organizational culture is determined by how the organizational leadership responds to a crisis, how they adapt to new demands and how they correct an employee when mistakes happen.

Moxifloxacin hydrochloride (Avelox) is indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria.

Meta-analysis of randomized controlled trials adds to growing evidence around certain antihypertensive drug classes showing promise for primary or secondary prevention of diabetes.

Part 3 in a series outlining 5 crucial steps pharmacies can take to enhance patient engagement and lower operational costs.

Health care professionals need to work closely with patients in understanding polypharmacy and the risk/benefit of pharmacotherapy.

Analysis supports positive lifestyle habits, such as exercising and quitting smoking, investigators say.

A new study predicts significant increases in cardiovascular issues in the United States, highlighting racial and ethnic inequality of future patients.

Pharmacists can play an important role in helping ensure compliance with prescribed medications, which can help seniors maintain their health and quality of life while aging at home.

Cangrelor (Kengreal) is indicated as an adjunct to percutaneous coronary intervention for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis.

Globally, more than 40 million patients are currently taking an ACE inhibitor, primarily for the treatment of high blood pressure and heart failure.

Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.

Tardive dyskinesia is often caused by the use of dopamine receptor blocking agents, most commonly antipsychotics, for at least a few months.

A systemic review found that recombinant zoster vaccination is more cost effective than no vaccine or the previously available zoster vaccine live.

Researchers recommend having a low clinical threshold for the diagnosis of Hashimoto’s encephalopathy in patients who reveal no apparent cause for their altered mental status, given the heterogenous nature of the condition’s presentation.

Last year, the majority of new drug approvals were for small molecules, including treatments for HIV, cancer, infections, heart and kidney disease, and neurological disorders.

The approval is based on results of the phase 3 study, ARASENS, that demonstrated a statistically significant increase in overall survival, the trial’s primary endpoint.

Preliminary data from the ongoing dose-escalation portion of the clinical trial, show dose-dependent anti-tumor activity when combined with standard-dose Libtayo.

Use of hormone therapy to treat prostate cancer may require more consideration by health care providers as new study shows the therapy may increase the risk of heart disease.

Based on overall response rate, acalabrutinib in tablet form is now FDA approved for all approved indications, enabling co-administration alongside a proton pump inhibitor.

Health care workers who got 4 total doses against COVID-19, 2 doses of which are boosters, experienced more than 10% lower breakthrough infection rate than those with only 3 total doses.

Dalteparin sodium (Fragmin) is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) to reduce VTE recurrence in adult patients with cancer, as well as several other indications.

Revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology, aligning with the Department of Health and Human Services’ roadmap.

The median overall survival of the lenvatinib monotherapy arm is longer than that observed in previous clinical trials evaluating it as a monotherapy for unresectable hepatocellular carcinoma.

The B-Clear study investigated the efficacy and safety of 12- or 24-weeks treatment with bepirovirsen in individuals with chronic hepatitis B.

Receiving a human papillomavirus vaccine and local surgical treatment could reduce the risk of recurring cervical lesions by 57%.